Renaissance Technologies (RenTech)'s IKT Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 16,500 shares of Inhibikase Therapeutics, Inc. (IKT) worth $27,720, representing 0.00% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in IKT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 16,500 shares. Largest reduction occurred in Q4 2024, reducing 19,922 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Inhibikase Therapeutics (IKT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Inhibikase Therapeutics (IKT) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +16,500 | New Buy | 16,500 | $1.68 |
| Q4 2024 | -19,922 | Sold Out | 0 | $0.00 |
| Q3 2024 | -900 | Reduce 4.32% | 19,922 | $1.30 |
| Q2 2024 | -600 | Reduce 2.80% | 20,822 | $1.21 |
| Q1 2024 | -3,000 | Reduce 12.28% | 21,422 | $2.15 |
| Q4 2023 | +8,300 | Add 51.48% | 24,422 | $1.27 |
| Q3 2023 | +3,400 | Add 26.73% | 16,122 | $1.36 |
| Q2 2023 | +1,505 | Add 13.42% | 12,722 | $0.00 |
| Q1 2023 | +2,550 | Add 29.42% | 11,217 | $0.00 |
| Q4 2022 | -12,113 | Reduce 58.29% | 8,667 | $0.00 |
| Q3 2022 | -16,203 | Reduce 43.81% | 20,780 | $5.44 |
| Q2 2022 | +5,571 | Add 17.74% | 36,983 | $4.46 |
| Q1 2022 | -2,121 | Reduce 6.33% | 31,412 | $8.88 |
| Q4 2021 | +33,533 | New Buy | 33,533 | $8.83 |
Renaissance Technologies (RenTech)'s Inhibikase Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Inhibikase Therapeutics, Inc. (IKT) in Q4 2021, acquiring 33,533 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Inhibikase Therapeutics, Inc. (IKT) for 14 quarters since Q4 2021.
Renaissance Technologies (RenTech)'s largest addition to Inhibikase Therapeutics, Inc. (IKT) was in Q4 2021, adding 33,533 shares worth $296,000.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 16,500 shares of Inhibikase Therapeutics, Inc. (IKT), valued at approximately $27,720.
As of the Q1 2026 filing, Inhibikase Therapeutics, Inc. (IKT) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Inhibikase Therapeutics, Inc. (IKT) was 36,983 shares, as reported at the end of Q2 2022.